From in vivo gene targeting of oestrogen receptors to optimization of their modulation in menopause

British Journal of Pharmacology

Volumn 165, Issue 1, 2012, Pages 57-66

  Arnal, Jean François ^a   Lenfant, Françoise ^a   Flouriot, Gilles ^c   Tremollières, Florence ^a   Laurell, Henrik ^a   Fontaine, Coralie ^a   Krust, Andrée ^b   Chambon, Pierre ^b   Gourdy, Pierre ^a  

^a Université de Toulouse   (France)

^b CNRS   (France)

^c UNIVERSITÉ DE RENNES 1   (France)

Author keywords

artery; atheroma; menopause; oestradiol; SERM; uterus

Indexed keywords

AFIMOXIFENE; BAZEDOXIFENE; CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FULVESTRANT; MEDROXYPROGESTERONE ACETATE; PLACEBO; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SEX HORMONE; TAMOXIFEN CITRATE;

ADJUVANT THERAPY; BREAST CANCER; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL FEATURE; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DRUG DESIGN; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; ENDOTHELIAL DYSFUNCTION; EPITHELIZATION; ERALPHA GENE; ERBETA GENE; ESTROGEN ACTIVITY; FRAGILITY FRACTURE; GENE; GENE TARGETING; HORMONE SUBSTITUTION; HUMAN; IN VIVO STUDY; ISCHEMIC HEART DISEASE; MENOPAUSAL SYNDROME; MENOPAUSE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; SYMPTOM; VASCULAR ENDOTHELIUM; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

ESTROGEN ANTAGONISTS; FEMALE; GENE TARGETING; HUMANS; MENOPAUSE; RECEPTORS, ESTROGEN;

EID: 82955177000     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01538.x     Document Type: Review

References (95)

1. Acconcia F, Ascenzi P, Bocedi A, Spisni E, Tomasi V, Trentalance A, et al,. (2005). Palmitoylation-dependent estrogen receptor alpha membrane localization: regulation by 17beta-estradiol. Mol Biol Cell 16: 231-237. (Pubitemid 40028339)
2. Akhter MP, Lappe JM, Davies KM, Recker RR, (2007). Transmenopausal changes in the trabecular bone structure. Bone 41: 111-116. (Pubitemid 46891901)
3. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, et al,. (2004). Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291: 1701-1712. (Pubitemid 38489892)
4. Anderson GL, Chlebowski RT, Rossouw JE, Rodabough RJ, McTiernan A, Margolis KL, et al,. (2006). Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin. Maturitas 55: 103-115. (Pubitemid 44307491)
5. Antal MC, Krust A, Chambon P, Mark M, (2008). Sterility and absence of histopathological defects in nonreproductive organs of a mouse ER beta-null mutant. Proc Natl Acad Sci USA 105: 2433-2438. (Pubitemid 351520531)
6. Arias-Loza PA, Jazbutyte V, Pelzer T, (2008). Genetic and pharmacologic strategies to determine the function of estrogen receptor alpha and estrogen receptor beta in cardiovascular system. Gend Med 5 (Suppl. A): S34-S45. (Pubitemid 351455230)
7. Arnal JF, Scarabin PY, Tremollieres F, Laurell H, Gourdy P, (2007). Estrogens in vascular biology and disease: where do we stand today? Curr Opin Lipidol 18: 554-560. (Pubitemid 47462209)
8. Arnal JF, Fontaine C, Billon-Gales A, Favre J, Laurell H, Lenfant F, et al,. (2010). Estrogen receptors and endothelium. Arterioscler Thromb Vasc Biol 30: 1506-1512.
9. Ascenzi P, Bocedi A, Marino M, (2006). Structure-function relationship of estrogen receptor alpha and beta: impact on human health. Mol Aspects Med 27: 299-402. (Pubitemid 44255847)
10. Banks E, Beral V, Reeves G, Balkwill A, Barnes I, (2004). Fracture incidence in relation to the pattern of use of hormone therapy in postmenopausal women. JAMA 291: 2212-2220. (Pubitemid 38608170)
11. Barrett-Connor E, (2007). Hormones and heart disease in women: the timing hypothesis. Am J Epidemiol 166: 506-510. (Pubitemid 47283648)
12. Beatson G, (1896). On treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 11: 104-107.
13. Berry M, Metzger D, Chambon P, (1990). Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen. EMBO J 9: 2811-2818.
14. Billon-Gales A, Fontaine C, Filipe C, Douin-Echinard V, Fouque MJ, Flouriot G, et al,. (2009). The transactivating function 1 of estrogen receptor alpha is dispensable for the vasculoprotective actions of 17 beta-estradiol. Proc Natl Acad Sci USA 106: 2053-2058.
15. Bolego C, Cignarella A, Sanvito P, Pelosi V, Pellegatta F, Puglisi L, et al,. (2005). The acute estrogenic dilation of rat aorta is mediated solely by selective estrogen receptor-alpha agonists and is abolished by estrogen deprivation. J Pharmacol Exp Ther 313: 1203-1208. (Pubitemid 40727023)
16. Bonds DE, Lasser N, Qi L, Brzyski R, Caan B, Heiss G, et al,. (2006). The effect of conjugated equine oestrogen on diabetes incidence: the Women's Health Initiative randomised trial. Diabetologia 49: 459-468. (Pubitemid 43277868)
17. Brouchet L, Krust A, Dupont S, Chambon P, Bayard F, Arnal JF, (2001). Estradiol accelerates reendothelialization in mouse carotid artery through estrogen receptor-alpha but not estrogen receptor-beta. Circulation 103: 423-428. (Pubitemid 32105983)
18. Brunner RL, Gass M, Aragaki A, Hays J, Granek I, Woods N, et al,. (2005). Effects of conjugated equine estrogen on health-related quality of life in postmenopausal women with hysterectomy: results from the Women's Health Initiative Randomized Clinical Trial. Arch Intern Med 165: 1976-1986. (Pubitemid 41362620)
19. Canonico M, Oger E, Plu-Bureau G, Conard J, Meyer G, Levesque H, et al,. (2007). Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 115: 840-845. (Pubitemid 46294724)
20. Cauley JA, Robbins J, Chen Z, Cummings SR, Jackson RD, LaCroix AZ, et al,. (2003). Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA 290: 1729-1738. (Pubitemid 37430623)
21. Chambliss KL, Wu Q, Oltmann S, Konaniah ES, Umetani M, Korach KS, et al,. (2010). Non-nuclear estrogen receptor alpha signaling promotes cardiovascular protection but not uterine or breast cancer growth in mice. J Clin Invest 120: 2319-2330.
22. Charn TH, Liu ET, Chang EC, Lee YK, Katzenellenbogen JA, Katzenellenbogen BS, (2010). Genome-wide dynamics of chromatin binding of estrogen receptors alpha and beta: mutual restriction and competitive site selection. Mol Endocrinol 24: 47-59.
23. Clarkson TB, Appt SE, (2005). Controversies about HRT-lessons from monkey models. Maturitas 51: 64-74.
24. Cooke PS, Heine PA, Taylor JA, Lubahn DB, (2001). The role of estrogen and estrogen receptor-alpha in male adipose tissue. Mol Cell Endocrinol 178: 147-154. (Pubitemid 32515358)
25. Couse JF, Korach KS, (1999). Estrogen receptor null mice: what have we learned and where will they lead us? Endocr Rev 20: 358-417. (Pubitemid 30654784)
26. Darblade B, Pendaries C, Krust A, Dupont S, Fouque MJ, Rami J, et al,. (2002). Estradiol alters nitric oxide production in the mouse aorta through the alpha-, but not beta-, estrogen receptor. Circ Res 90: 413-419. (Pubitemid 34633910)
27. Donahue RP, Bean JA, Donahue RA, Goldberg RB, Prineas RJ, (1997). Insulin response in a triethnic population: effects of sex, ethnic origin, and body fat. Miami Community Health Study. Diabetes Care 20: 1670-1676.
28. Dubey RK, Imthurn B, Barton M, Jackson EK, (2005). Vascular consequences of menopause and hormone therapy: importance of timing of treatment and type of estrogen. Cardiovasc Res 66: 295-306. (Pubitemid 40471044)
29. Dupont S, Krust A, Gansmuller A, Dierich A, Chambon P, Mark M, (2000). Effect of single and compound knockouts of estrogen receptors alpha (ERalpha) and beta (ERbeta) on mouse reproductive phenotypes. Development 127: 4277-4291.
30. Edwards DP, (2005). Regulation of signal transduction pathways by estrogen and progesterone. Annu Rev Physiol 67: 335-376. (Pubitemid 40409510)
31. Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Willett WC, Rosner B, et al,. (1996). Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 335: 453-461. (Pubitemid 26269944)
32. Hartman J, Lindberg K, Morani A, Inzunza J, Strom A, Gustafsson JA, (2006). Estrogen receptor beta inhibits angiogenesis and growth of T47D breast cancer xenografts. Cancer Res 66: 11207-11213. (Pubitemid 46009948)
33. Hays J, Ockene JK, Brunner RL, Kotchen JM, Manson JE, Patterson RE, et al,. (2003). Effects of estrogen plus progestin on health-related quality of life. N Engl J Med 348: 1839-1854. (Pubitemid 36532310)
34. Heine PA, Taylor JA, Iwamoto GA, Lubahn DB, Cooke PS, (2000). Increased adipose tissue in male and female estrogen receptor-alpha knockout mice. Proc Natl Acad Sci USA 97: 12729-12734.
35. Herrington DM, Klein KP, (2001). Invited review: pharmacogenetics of estrogen replacement therapy. J Appl Physiol 91: 2776-2784.
36. Holm P, Andersen HL, Andersen MR, Erhardtsen E, Stender S, (1999). The direct antiatherogenic effect of estrogen is present, absent, or reversed, depending on the state of the arterial endothelium. A time course study in cholesterol-clamped rabbits. Circulation 100: 1727-1733. (Pubitemid 29485256)
37. Horwitz KB, (2008). The Year in Basic Science: update of estrogen plus progestin therapy for menopausal hormone replacement implicating stem cells in the increased breast cancer risk. Mol Endocrinol 22: 2743-2750.
38. Huet G, Merot Y, Percevault F, Tiffoche C, Arnal JF, Boujrad N, et al,. (2009). Repression of the estrogen receptor-alpha transcriptional activity by the Rho/megakaryoblastic leukemia 1 signaling pathway. J Biol Chem 284: 33729-33739.
39. Iafrati MD, Karas RH, Aronovitz M, Kim S, Sullivan TR Jr, Lubahn DB, et al,. (1997). Estrogen inhibits the vascular injury response in estrogen receptor alpha-deficient mice. Nat Med 3: 545-548. (Pubitemid 27198653)
40. Jensen EV, Jacobson HI, Walf AA, Frye CA, (2010). Estrogen action: a historic perspective on the implications of considering alternative approaches. Physiol Behav 99: 151-162.
41. Jordan VC, (2001). The past, present, and future of selective estrogen receptor modulation. Ann N Y Acad Sci 949: 72-79. (Pubitemid 34059963)
42. Jordan VC, (2003). Tamoxifen: a most unlikely pioneering medicine. Nat Rev Drug Discov 2: 205-213. (Pubitemid 37361665)
43. Kalin MF, Zumoff B, (1990). Sex hormones and coronary disease: a review of the clinical studies. Steroids 55: 330-352. (Pubitemid 20309765)
44. Kanaya AM, Herrington D, Vittinghoff E, Lin F, Grady D, Bittner V, et al,. (2003). Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin Replacement Study. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 138: 1-9. (Pubitemid 36232088)
45. Karas RH, Schulten H, Pare G, Aronovitz MJ, Ohlsson C, Gustafsson JA, et al,. (2001). Effects of estrogen on the vascular injury response in estrogen receptor alpha, beta (double) knockout mice. Circ Res 89: 534-539. (Pubitemid 34133991)
46. Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, et al,. (1995). Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270: 1491-1494.
47. Katzenellenbogen BS, Katzenellenbogen JA, (2002). Biomedicine. Defining the 'S' in SERMs. Science 295: 2380-2381.
48. Kim KH, Bender JR, (2009). Membrane-initiated actions of estrogen on the endothelium. Mol Cell Endocrinol 308: 3-8.
49. Koh KK, Yoon BK, (2006). Controversies regarding hormone therapy: insights from inflammation and hemostasis. Cardiovasc Res 70: 22-30.
50. Komulainen MH, Kroger H, Tuppurainen MT, Heikkinen AM, Alhava E, Honkanen R, et al,. (1998). HRT and Vit D in prevention of non-vertebral fractures in postmenopausal women; a 5 year randomized trial. Maturitas 31: 45-54. (Pubitemid 29050890)
51. Kos M, Denger S, Reid G, Korach KS, Gannon F, (2002). Down but not out? A novel protein isoform of the estrogen receptor alpha is expressed in the estrogen receptor alpha knockout mouse. J Mol Endocrinol 29: 281-286. (Pubitemid 36024544)
52. Kousteni S, Bellido T, Plotkin LI, O'Brien CA, Bodenner DL, Han L, et al,. (2001). Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell 104: 719-730. (Pubitemid 32241022)
53. Kraichely DM, Sun J, Katzenellenbogen JA, Katzenellenbogen BS, (2000). Conformational changes and coactivator recruitment by novel ligands for estrogen receptor-alpha and estrogen receptor-beta: correlations with biological character and distinct differences among SRC coactivator family members. Endocrinology 141: 3534-3545.
54. Krust A, Green S, Argos P, Kumar V, Walter P, Bornert JM, et al,. (1986). The chicken oestrogen receptor sequence: homology with v-erbA and the human oestrogen and glucocorticoid receptors. EMBO J 5: 891-897.
55. de Lauzon-Guillain B, Fournier A, Fabre A, Simon N, Mesrine S, Boutron-Ruault MC, et al,. (2009). Menopausal hormone therapy and new-onset diabetes in the French Etude Epidemiologique de Femmes de la Mutuelle Generale de l'Education Nationale (E3N) cohort. Diabetologia 52: 2092-2100.
56. Lenfant F, Tremollieres F, Gourdy P, Arnal JF, (2011). Timing of the vascular actions of estrogens in experimental and human studies: why protective early, and not when delayed? Maturitas 68: 165-173.
57. Levin ER, (2005). Integration of the extranuclear and nuclear actions of estrogen. Mol Endocrinol 19: 1951-1959. (Pubitemid 41124194)
58. Liu S, Mauvais-Jarvis F, (2010). Minireview: estrogenic protection of beta-cell failure in metabolic diseases. Endocrinology 151: 859-864.
59. Louet JF, LeMay C, Mauvais-Jarvis F, (2004). Antidiabetic actions of estrogen: insight from human and genetic mouse models. Curr Atheroscler Rep 6: 180-185. (Pubitemid 38898916)
60. Lu Q, Pallas DC, Surks HK, Baur WE, Mendelsohn ME, Karas RH, (2004). Striatin assembles a membrane signaling complex necessary for rapid, nongenomic activation of endothelial NO synthase by estrogen receptor alpha. Proc Natl Acad Sci USA 101: 17126-17131. (Pubitemid 39627785)
61. Lubahn DB, Moyer JS, Golding TS, Couse JF, Korach KS, Smithies O, (1993). Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene. Proc Natl Acad Sci USA 90: 11162-11166. (Pubitemid 23354389)
62. McKenna NJ, O'Malley BW, (2002). Combinatorial control of gene expression by nuclear receptors and coregulators. Cell 108: 465-474. (Pubitemid 34260872)
63. Maki PM, Gast MJ, Vieweg AJ, Burriss SW, Yaffe K, (2007). Hormone therapy in menopausal women with cognitive complaints: a randomized, double-blind trial. Neurology 69: 1322-1330. (Pubitemid 47482446)
64. Margolis KL, Bonds DE, Rodabough RJ, Tinker L, Phillips LS, Allen C, et al,. (2004). Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women's Health Initiative Hormone Trial. Diabetologia 47: 1175-1187. (Pubitemid 39093314)
65. Mendelsohn ME, Karas RH, (2005). Molecular and cellular basis of cardiovascular gender differences. Science 308: 1583-1587. (Pubitemid 40807497)
66. Merot Y, Metivier R, Penot G, Manu D, Saligaut C, Gannon F, et al,. (2004). The relative contribution exerted by AF-1 and AF-2 transactivation functions in estrogen receptor alpha transcriptional activity depends upon the differentiation stage of the cell. J Biol Chem 279: 26184-26191. (Pubitemid 38798764)
67. Metivier R, Penot G, Hubner MR, Reid G, Brand H, Kos M, et al,. (2003). Estrogen receptor-alpha directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter. Cell 115: 751-763. (Pubitemid 38030303)
68. Metzger D, Clifford J, Chiba H, Chambon P, (1995). Conditional site-specific recombination in mammalian cells using a ligand-dependent chimeric Cre recombinase. Proc Natl Acad Sci USA 92: 6991-6995.
69. Meyers MJ, Sun J, Carlson KE, Marriner GA, Katzenellenbogen BS, Katzenellenbogen JA, (2001). Estrogen receptor-beta potency-selective ligands: structure-activity relationship studies of diarylpropionitriles and their acetylene and polar analogues. J Med Chem 44: 4230-4251. (Pubitemid 33095330)
70. Miyagawa K, Rosch J, Stanczyk F, Hermsmeyer K, (1997). Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm. Nat Med 3: 324-327. (Pubitemid 27112931)
71. Nadal A, Alonso-Magdalena P, Soriano S, Quesada I, Ropero AB, (2009). The pancreatic beta-cell as a target of estrogens and xenoestrogens: implications for blood glucose homeostasis and diabetes. Mol Cell Endocrinol 304: 63-68.
72. National Center for Health Statistics (2004). Table 27. Life expectancy at birth at 65 years of age, and at 75 years age brackets according to race. US, selected years 1900-2004. Available at (accessed: April 17, 2011).
73. Nuutila P, Knuuti MJ, Maki M, Laine H, Ruotsalainen U, Teras M, et al,. (1995). Gender and insulin sensitivity in the heart and in skeletal muscles. Studies using positron emission tomography. Diabetes 44: 31-36.
74. Pare G, Krust A, Karas RH, Dupont S, Aronovitz M, Chambon P, et al,. (2002). Estrogen receptor-alpha mediates the protective effects of estrogen against vascular injury. Circ Res 90: 1087-1092. (Pubitemid 34627907)
75. Paruthiyil S, Parmar H, Kerekatte V, Cunha GR, Firestone GL, Leitman DC, (2004). Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res 64: 423-428. (Pubitemid 38114127)
76. Pendaries C, Darblade B, Rochaix P, Krust A, Chambon P, Korach KS, et al,. (2002). The AF-1 activation-function of ER alpha may be dispensable to mediate the effect of estradiol on endothelial NO production in mice. Proc Natl Acad Sci USA 99: 2205-2210. (Pubitemid 34169039)
77. Razandi M, Pedram A, Park ST, Levin ER, (2003). Proximal events in signaling by plasma membrane estrogen receptors. J Biol Chem 278: 2701-2712. (Pubitemid 36801351)
78. Renoux C, Dell'aniello S, Garbe E, Suissa S, (2010). Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. BMJ 340: c2519.
79. Riant E, Waget A, Cogo H, Arnal JF, Burcelin R, Gourdy P, (2009). Estrogens protect against high-fat diet-induced insulin resistance and glucose intolerance in mice. Endocrinology 150: 2109-2117.
80. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al,. (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 288: 321-333. (Pubitemid 34761611)
81. Rossouw JE, Prentice RL, Manson JE, Wu L, Barad D, Barnabei VM, et al,. (2007). Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 297: 1465-1477. (Pubitemid 46556472)
82. Shang Y, Brown M, (2002). Molecular determinants for the tissue specificity of SERMs. Science 295: 2465-2468. (Pubitemid 34270263)
83. Simoncini T, (2009). Mechanisms of action of estrogen receptors in vascular cells: relevance for menopause and aging. Climacteric 12 (Suppl. 1): 6-11.
84. Smith CL, O'Malley BW, (2004). Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr Rev 25: 45-71. (Pubitemid 38292038)
85. Smith EP, Boyd J, Frank GR, Takahashi H, Cohen RM, Specker B, et al,. (1994). Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 331: 1056-1061. (Pubitemid 24317698)
86. Stevenson JC, Hodis HN, Pickar JH, Lobo RA, (2009). Coronary heart disease and menopause management: the swinging pendulum of HRT. Atherosclerosis 207: 336-340.
87. Strom A, Hartman J, Foster JS, Kietz S, Wimalasena J, Gustafsson JA, (2004). Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D. Proc Natl Acad Sci USA 101: 1566-1571. (Pubitemid 38236167)
88. Tora L, White J, Brou C, Tasset D, Webster N, Scheer E, et al,. (1989). The human estrogen receptor has two independent nonacidic transcriptional activation functions. Cell 59: 477-487. (Pubitemid 19284461)
89. Tzukerman MT, Esty A, Santiso-Mere D, Danielian P, Parker MG, Stein RB, et al,. (1994). Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. Mol Endocrinol 8: 21-30. (Pubitemid 24034253)
90. Wedisinghe L, Perera M, (2009). Diabetes and the menopause. Maturitas 63: 200-203.
91. Wehrli FW, Ladinsky GA, Jones C, Benito M, Magland J, Vasilic B, et al,. (2008). In vivo magnetic resonance detects rapid remodeling changes in the topology of the trabecular bone network after menopause and the protective effect of estradiol. J Bone Miner Res 23: 730-740. (Pubitemid 351575027)
92. Wells G, Tugwell P, Shea B, Guyatt G, Peterson J, Zytaruk N, et al,. (2002). Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocr Rev 23: 529-539. (Pubitemid 34925647)
93. Welton AJ, Vickers MR, Kim J, Ford D, Lawton BA, MacLennan AH, et al,. (2008). Health related quality of life after combined hormone replacement therapy: randomised controlled trial. BMJ 337: a1190.
94. Wong CW, McNally C, Nickbarg E, Komm BS, Cheskis BJ, (2002). Estrogen receptor-interacting protein that modulates its nongenomic activity-crosstalk with Src/Erk phosphorylation cascade. Proc Natl Acad Sci USA 99: 14783-14788. (Pubitemid 35334561)
95. Zhao C, Dahlman-Wright K, Gustafsson JA, (2008). Estrogen receptor beta: an overview and update. Nucl Recept Signal 6: e003.